High Potency Active Pharmaceutical Ingredients (HPAPIs) Market Key Player Strategies
Companies dealing in the high potency active pharmaceutical ingredients (APIs) market are focusing on strategies such as production facility expansion and mergers & acquisitions to maintain their position in the competitive business environment. For instance, in 2017, Piramal Enterprises, an India based pharmaceuticals company, invested $55 million to enhance the capabilities of its five API manufacturing plants in India and the US. In the following year, in October 2018, Lonza, a Switzerland based specialty contract development and manufacturing organization (CDMO) in the biopharma industry, announced the expansion of its potent API (HPAPI) capacity by adding two new sites in order to support its antibody-drug conjugates (ADC) payload manufacturing.
In August 2019, Permira Funds, a UK based global investment firm, acquired Cambrex Corporation for USD 2.4 million. Through the acquisition, Permira Funds will provide financial support to Cambrex Corporation for the expansion of its product manufacturing and analytical testing services. Cambrex Corporation is a life sciences company that offers products and services for small molecule active pharmaceutical ingredients. The company is headquartered in the US.
Key players in the global HP (high potency) APIs market include Eli Lily and Company, Novartis AG, Bristol-Myers Squibb Company, Roche Diagnostics Ltd., Sanofi, Hospira, Inc., BASF SE, Covidien plc, Boehringer Ingelheim GmbH, Merck & Co., Inc., Sigma Aldrich Corporation, Bayer AG, Carbogen Amcis AG, Lonza, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Mylan, Inc. , AbbVie, AstraZeneca plc, and GlaxoSmithKline PLC.
The high potency APIs (HPAPI) market consists of sales of high potency active pharmaceutical ingredients and related services. High potency APIs are extremely effective in pharmacologically active ingredients. These are highly specific in their action and offer significant efficiency even at the low daily therapeutic doses. HPAPIs are used in formulations for high potent drugs, owing to their ability to target precise disease cells including cancer cells.
The global high potency APIs (HPAPI) market is expected to decline from $19.7 billion in 2019 to $18.5 billion in 2020 at a compound annual growth rate (CAGR) of -6%. The decline is mainly due to the focus on the Covid-19 outbreak and its treatment across the globe, resulting in patients of other illnesses including cancer and other immunodeficiency diseases delaying their episodes of care. Restrictions on trade and exports owing to the lockdown of countries that manufacture the drug is also hindering market growth. The market is then expected to recover and reach $24.1 billion in 2023 at a CAGR of 5.2%.
The high potency APIs (HPAPI) market is segmented by type into innovative HPAPI, and generic HPAPI. It is also segmented by synthesis type into synthetic HPAPI, and biotech HPAPI, and by therapeutic application into oncology, hormonal disorder, glaucoma, and other therapeutic applications (respiratory disorders, CVD, diabetes, cosmetology, and erectile dysfunction).